This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stewart, C. F. Articles by Evans, W. E. Search for Related Content PubMed PubMed Citation Articles by Stewart, C. F. Articles by Evans, W. E.

Prospective Evaluation of a Model for Predicting Etoposide Plasma Protein Binding in Cancer Patients¹

Department of Clinical Pharmacy, University of Tennessee, Memphis, Memphis, Tennessee 31863 [C. F. S., R. A. F., W. E. E.]; Department of Medicine, Roswell Park Memorial Institute, Buffalo, New York 14203 [S. G. A.]; and Pharmaceutical Division, St. Jude Children's Research Hospital, Memphis, Tennessee 38101 [W. E. E.]

Etoposide protein binding in cancer patients is variable and has been related mathematically to a linear model consisting of serum albumin and total bilirubin [percentage unbound = (1.4 x total bilirubin) - (6.8 x albumin) + 34.4]. In this prospective evaluation of the model, plasma samples were obtained following the administration of etoposide in 31 patients, and the unbound percentage (% unbound) of etoposide in plasma was determined by equilibrium dialysis. The mean measured % unbound was 15.3 ± 11.6 (SD), and the mean model predicted % unbound was 16.7 ± 10.1. The relation between predicted and measured etoposide % unbound was highly correlated (r² = 0.92, P = 0.001). The model was precise but with a slight bias toward overpredicting % unbound (mean prediction error, 1.36%; 95% confidence interval, 0.09 to 2.6%). In patients with abnormal total bilirubin (i.e., >1.5 mg/dl) or with hypoal-buminemia (i.e., <3.3 g/dl), the model was both precise and unbiased. These results demonstrate that etoposide % unbound can be predicted using serum albumin and total bilirubin. This model should be useful in prospectively identifying patients at increased risk of experiencing altered pharmacological effects due to altered protein binding of etoposide.

¹ This work was supported in part by NIH grants R37-CA36401, CA-34184, Cancer Center CORE Grant CA-21765, and ALSAC.

² To whom requests for reprints should be addressed.

Received 5/10/90. Accepted 7/31/90.

This article has been cited by other articles:

				C. Kloft, J. Wallin, A. Henningsson, E. Chatelut, and M. O. Karlsson Population Pharmacokinetic-Pharmacodynamic Model for Neutropenia with Patient Subgroup Identification: Comparison across Anticancer Drugs. Clin. Cancer Res., September 15, 2006; 12(18): 5481 - 5490. [Abstract] [Full Text] [PDF]